UCSF researchers have developed a novel small molecule drug that specifically targets and inhibits SLC26A3 (DRA), an anion exchanger whose inhibition is expected to have therapeutic benefit in constipation and oxalate kidney stone disease.
Chronic constipation and kidney stone disease are exceedingly common diseases in the U.S and around the world, with a high recurrence rate. Each year in the U.S., chronic constipation leads to around 2.5 million doctor visits and medication costs of millions of dollars, making it one of the most expensive digestive disorders to treat. The incidence of kidney stones in the United States is between 7-13% and has been steadily rising over time. Calcium oxalate stones are the most common type of kidney stone. Most available medications for chronic constipation have limited efficacy. There are currently no drugs to treat kidney stones, which can require expensive and invasive procedures to treat. This invention describes a first-in-class inhibitor of SLC26A3, a major anion exchanger responsible for facilitating intestinal fluid and oxalate absorption.
This new class of small molecule drugs provides the following advantages:
Researchers at University of California, San Francisco have identified a novel small molecule inhibitor of SLC26A3, an intestinal anion exchanger that regulates fluid and oxalate absorption in the colon. This drug selectively inhibits SLC26A3 with high potency, without affecting related proteins. Oral administration of drug in mice effectively reduced signs of constipation, with increased efficacy in combination with other drugs.
To develop and commercialize this technology as a therapy for constipation and oxalate kidney stone disease.
Therapy for chronic idiopathic constipation, irritable bowel syndrome (IBS) with constipation, and calcium oxalate kidney stone disease.
Constipation, Irritable Bowel Syndrome (IBS), Calcium Oxalate Kidney Stone, Small Molecule Drug, Anion Exchanger